

WuXi Biologics and HanchorBio advances next-generation Bi- and Multi-functional fusion protein pipeline

29 January 2026 | News

To support continued expansion of proprietary FBDB™ technology platform



WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc., a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, have jointly announced the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programmes from HanchorBio's pipeline.

Under the agreement, China-based WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing.

The collaboration is designed to enhance CMC execution efficiency, accelerate clinical translation, and support scalable global development and manufacturing of HanchorBio's innovative fusion protein portfolio derived from its Fc-Based Designer Biologics (FBDB™) platform.

This partnership reflects HanchorBio's strategy to advance its platform-derived, multi-asset pipelines with development speed, manufacturing robustness, and capital efficiency from early clinical stages through commercialisation. By leveraging WuXi Biologics' proven capabilities in complex biologics and its global quality systems, HanchorBio aims to shorten development timelines and maintain flexibility across multiple clinical programs.

Image caption- Dr Chris Chen (right), CEO of WuXi Biologics, and Dr Scott Liu (left), Founder, Chairman, and CEO of HanchorBio